Rodney Prell
Senior Fellow (Dev Sci), Safety Assessment
"It has been a privilege to work in Safety Assessment at Genentech, where we take patient safety as our highest priority."
I received my PhD and postdoctoral training in immunotoxicology and cancer immunotherapy, respectively. I joined Genentech as a scientist/toxicologist in 2007 after six years of cancer immunotherapy pharmacology and toxicology research in small biotech in the San Francisco Bay Area. My initial responsibilities were mainly as a project team toxicologist where I designed and implemented non-clinical safety studies to support INDs through BLAs. I am currently a Staff Scientist/Toxicologist and Safety Assessment Therapeutic Area Lead for Cancer Immunology, where I have oversight for the safety assessment strategy for the Cancer Immunology portfolio. I am a Diplomat of the American Board of Toxicology (DABT) since 2004.
Featured Publication
Perspective on a Modified Developmental and Reproductive Toxicity Testing Strategy for Cancer Immunotherapy.
Int J Toxicol 2016 35(3): 263-273.
Prell, R.A., Halpern W.G. and Rao, G.
My focus area is the safety assessment of new molecular entities in cancer immunology. This area spans a wide variety of platforms and modalities and as such, requires flexible approaches for nonclinical safety to support first in human studies and appropriate first in human dose selection. We are exploring ways to improve the existing or develop novel nonclinical safety models support cancer immunology drug development.
- Oregon State University, Ph.D. Toxicology Program (Immunotoxicology) – 1997
- University of Wisconsin-Madison, Biochemistry, B.S. – 1989